Cor Vasa 2007, 49(9):327-332 | DOI: 10.33678/cor.2007.115

Genetics in cardiology. Part IV. Polygenic cardiovascular disease. Potential for gene therapy in cardiology

Ilga Grochová1, Ladislav Groch2
1 Genprogress s. r. o. Brno, Centrum prenatální diagnostiky s. r. o
2 I. interní-kardioangiologická klinika, Fakultní nemocnice u sv. Anny, Brno, Česká republika

Part IV of the series discusses the associations between gene polymorphisms and environmental factors in polygenic diseases such as coronary heart disease including myocardial infarction. Despite the hundreds of studies reporting dozens of gene polymorphisms, controversy remains; practical use of genetics including gene therapy in polygenic disease is a matter of future (hopefully not too distant).

Keywords: Gene polymorphism; Multifactorial inheritance; Gene therapy

Published: September 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grochová I, Groch L. Genetics in cardiology. Part IV. Polygenic cardiovascular disease. Potential for gene therapy in cardiology. Cor Vasa. 2007;49(9):327-332. doi: 10.33678/cor.2007.115.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ridker PM, Hennekens CH, Lindpaintner K, et al. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation 1997;95:59-62. Go to original source... Go to PubMed...
    2. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67-70. Go to original source... Go to PubMed...
    3. Rundek T, Elkind MS, Pittman J, et al. Carotid intimamedia thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 2002;33:1420-3. Go to original source... Go to PubMed...
    4. Broeckel U, Hengstenberg C, Mayer B, et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 2002;30:210-4. Go to original source... Go to PubMed...
    5. Newman D, Hoffjan S, Bourgain C, et al. Are common disease susceptibility alleles the same in outbred and founder populations? Eur J Hum Gen 2004;12:584-90. Go to original source... Go to PubMed...
    6. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl J Med 1998;338:86-93. Go to original source... Go to PubMed...
    7. Inoue N, Kawashima S, Kanazawa K, et al. Polymorphism of the NADH/NADPH oxidase p22 phox gene in patients with coronary artery disease. Circulation 1998;97:135-7. Go to original source... Go to PubMed...
    8. Yamada Y, Izawa H, Ichihara S. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. Hypertens 2003;12:13-4. Go to original source...
    9. Morgan T, Harlan M, et al. Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study. JAMA 2007;297:1551-61. Go to original source... Go to PubMed...
    10. Topol E, Smith J, Plow J, et al. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Gen 2006;15:R117-R123. Go to original source... Go to PubMed...
    11. Luo AK, Jefferson B,Garcia M, et al. Challenges in the phenotypic characterisation of patients in genetic studies of coronary artery disease. J Med Gen 2007; 44:161-5 Go to original source... Go to PubMed...
    12. The International HapMap Consortium: A haplotype map of the human genome. Nature 2005;437:1299-320. Go to original source... Go to PubMed...
    13. Kimberly S, Glenn G, Simari R, et al. The effect of HapMap on cardiovascular research and clinical practice. Nat Clin Pract Cardiovasc Med 2007;4:136-42. Go to original source... Go to PubMed...
    14. Wang L, Fan CH, Topol E, et al. Mutation of MEF2A in an Inherited Disorder with Features of Coronary Artery Disease. Science 2003;302:1578-81. Go to original source... Go to PubMed...
    15. Bhagavatula K, Chun F, Gong-Qing Sh, et al. Transcription factor MEF2A mutations in patients with coronary artery disease. Hum Mol Gen 2004;13:3181-8. Go to original source... Go to PubMed...
    16. Morishita R, Aoki M, Ogihara T. Does gene therapy become farmacotherapy? Exp Physiol 2005;90:307-13. Go to original source... Go to PubMed...
    17. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7. Go to original source... Go to PubMed...
    18. Heilmann C, von Samson P, Schlegel K, et al. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 2002;22:957-64. Go to original source... Go to PubMed...
    19. Yonemitsu Y, Kaneda Y, Tanaka S. Transfer of wild-type p53 gene effectively inhibits vascular smooth muscle cell proliferation in vitro and in vivo. Circ Res 1998;82:147-56. Go to original source... Go to PubMed...
    20. Igata M, Motoshima H, Tsuruzoe K, et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005; 97:837-44. Go to original source... Go to PubMed...
    21. Andres V. Unexpected proatherogenic properties of p21: Beyond cell cycle control? Circulation 2004;110: 3749-52. Go to original source... Go to PubMed...
    22. Sata M, Tanaka K, Ishizaka N, et al. Absence of p53 leads to accelerated neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2003; 23:1548-52. Go to original source... Go to PubMed...
    23. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ Res 2000;87:184-8. Go to original source... Go to PubMed...
    24. Piťha J, Hubáček JA, Poledne R, et al. Genetic determination of the prognosis in survivors of acute coronary syndromes. Study design and rationale for a multicenter study. Cor Vasa 2007;49:134-7. Go to original source...
    25. Isner J. Still more debate over VEGF. Nat Med 2001;7: 639-41. Go to original source... Go to PubMed...
    26. Gonzales P, Garcia-Castro M, Reguero JR, et al. The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction. J Med Genet 2006;43:167-9. Go to original source... Go to PubMed...
    27. Ozaki K, Tanaka T. Genome-wide association study to identify single-nucleotide polymorphisms conferring risk of myocardial infarction. Methods Mol Med 2006; 128:173-80. Go to original source... Go to PubMed...
    28. Weng L, Kavaslar N, Ustaszewska A, et al. Lack of MEF2A mutations in coronary artery disease. J Clin Invest 2005;115:1016-20. Go to original source... Go to PubMed...
    29. Nissen S, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomised controlled trial. JAMA 2003;290:2292-300. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes